You may also receive Jemperli if you have endometrial cancer that has come back. Your health care provider may test you for a biomarker known as mismatch repair deficiency ...

Jemperli's earlier indications across endometrial cancer and dMMR solid tumours have generated modest revenues, coming in at £36 million ($46 million) in the first six months of this year and ...

Jemperli, a cancer drug manufactured by GlaxoSmithKline, improved survival for patients diagnosed with a form of uterine cancer by more than one year, the British drugmaker said Saturday, the ...

By GSK’s reckoning, there are around 60,000 new cases of endometrial cancer diagnosed each year in the US, with 15% to 20% of them at the advanced or metastatic stage. Of these, 20% to 29% are ...

The FDA has approved a new drug for some adult patients with endometrial cancer. Jemperli (dostarlimably) — made by U.K. company GSK — is intended for primary advanced or recurrent disease.

Recurrent endometrial cancer is cancer that returns after treatment, often in the pelvis, ... (Jemperli) pembrolizumab (Keytruda) and block a protein called PD-1 on immune cells.

Jemperli is already approved by the FDA to treat adult patients with dMMR recurrent or advanced endometrial cancer and solid tumors. Shares of GSK have declined 0.3% compared with the industry ...

Based on these results, Jemperli’s current approval could expand from exclusively the dMMR-MSI-H population to all primary advanced or recurrent endometrial cancer patients as another first-line ...

"EC approves GSK’s Jemperli-chemo combo for endometrial cancer" was originally created and published by Pharmaceutical ...

GSK's cancer study met its primary endpoint of progression-free survival. Endometrial cancer is the most common gynecologic cancer in developed countries, with approximately 417,000 new cases ...